STOCK TITAN

OKYO (NASDAQ: OKYO) CMO Mantelli reports multi-year option holdings in Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

OKYO Pharma Ltd filed a Form 3 for Chief Medical Officer Flavio Mantelli, disclosing his holdings of company share options. The filing lists four option positions over common stock, each tied to 187,500 underlying shares.

All options carry an exercise price of $1.96 per share and an expiration date in 2036. The options have scheduled exercise (vesting) dates in 2027, 2028, 2029, and 2030, showing when they become exercisable if conditions are met. This Form 3 records Mantelli’s existing derivative holdings rather than any new market transaction.

Positive

  • None.

Negative

  • None.
Insider Mantelli Flavio
Role CHIEF MEDICAL OFFICER
Type Security Shares Price Value
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
Holdings After Transaction: Options — 187,500 shares (Direct, null)
Footnotes (1)
Options tranche 1 underlying shares 187,500 shares Underlying common stock for first option holding
Options tranche 2 underlying shares 187,500 shares Underlying common stock for second option holding
Options tranche 3 underlying shares 187,500 shares Underlying common stock for third option holding
Options tranche 4 underlying shares 187,500 shares Underlying common stock for fourth option holding
Exercise price $1.96 per share Conversion or exercise price for all reported options
First scheduled exercise date 2027-02-10 Earliest exercise date among reported option holdings
Latest scheduled exercise date 2030-02-10 Latest initial exercise date among reported option holdings
Options expiration date 2036-02-10 Common expiration date for all disclosed options
Options financial
"security_title": "Options""
Options are contracts that give investors the right to buy or sell an asset at a specific price within a certain time frame. They function like a reservation or a ticket that allows for potential profit or protection against price changes, making them useful tools for managing investment risks or speculating on market movements.
Common stock financial
"underlying_security_title": "Common stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price": "1.9600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-02-10T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Mantelli Flavio

(Last)(First)(Middle)
C/O OKYO PHARMA LTD,
14-15 CONDUIT STREET

(Street)
LONDONW1S 2XJ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF MEDICAL OFFICER
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options02/10/202702/10/2036Common stock187,500$1.96D
Options02/10/202802/10/2036Common stock187,500$1.96D
Options02/10/202902/10/2036Common stock187,500$1.96D
Options02/10/203002/10/2036Common stock187,500$1.96D
Explanation of Responses:
/s/ Flavio Mantelli06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the OKYO Form 3 for Flavio Mantelli show?

The Form 3 shows Chief Medical Officer Flavio Mantelli’s existing option holdings in OKYO Pharma. It lists four option positions over common stock, each linked to 187,500 underlying shares at a $1.96 exercise price, with expirations in 2036.

How many OKYO shares are covered by Flavio Mantelli’s options?

Each of the four disclosed option positions is tied to 187,500 underlying OKYO common shares. These options have a $1.96 per share exercise price and expire in 2036, with different scheduled exercise dates between 2027 and 2030.

What is the exercise price of Flavio Mantelli’s OKYO options?

All reported options held by Flavio Mantelli have a $1.96 per share exercise price. This is the price he would pay to convert each option into OKYO common stock once the options become exercisable between 2027 and 2030.

When do Flavio Mantelli’s OKYO options become exercisable and expire?

The options have scheduled exercise dates in 2027, 2028, 2029, and 2030, indicating when they can first be exercised. Each option position shares a common expiration date in 2036, after which unexercised options lapse and can no longer be converted.

Does the OKYO Form 3 show Flavio Mantelli buying or selling shares?

The Form 3 does not show any buy or sell transactions. It records Mantelli’s existing derivative holdings—options over OKYO common stock—with specified exercise prices, vesting years from 2027 to 2030, and a 2036 expiration date for each option position.

What type of securities are reported in Flavio Mantelli’s OKYO Form 3?

The Form 3 reports derivative securities in the form of options over OKYO common stock. Each option position references 187,500 underlying common shares, has a $1.96 exercise price, future exercise dates between 2027 and 2030, and a common 2036 expiration date.